Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
Eyenovia to discontinue late-stage study for eye drug
Why Is Eye Disease Focused Eyenovia Stock Trading Higher On Thursday?